

# Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

## RIL-175

RRID:CVCL\_B7TK

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_B7TK

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_B7TK](https://web.expasy.org/cellosaurus/CVCL_B7TK)

**Proper Citation:** RRID:CVCL\_B7TK

**Description:** Cell line RIL-175 is a Cancer cell line with a species of origin Mus musculus (Mouse)

**Sex:** Sex unspecified

**Disease:** Hepatocellular carcinoma of the mouse

**Defining Citation:** [PMID:23796475](#), [PMID:32652772](#)

**Category:** Cancer cell line

**Organism:** Mus musculus (Mouse)

**Name:** RIL-175

**Synonyms:** RIL175

**Cross References:** Wikidata:Q114312786

**ID:** CVCL\_B7TK

**Record Creation Time:** 20220624T071252+0000

**Record Last Update:** 20260726T000717+0000

---

### Ratings and Alerts

No rating or validation information has been found for RIL-175.

No alerts have been found for RIL-175.

## Data and Source Information

**Source:** [CelloSaurus](#)

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Teo JMN, et al. (2025) Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma. The Journal of experimental medicine, 222(1).

Yeung CLS, et al. (2025) Identification of molecular markers and exploration of the oncogenic role of exomeres in hepatocellular carcinoma. Cell reports, 44(11), 116460.

Morita S, et al. (2024) Combination CXCR4 and PD1 blockade enhances intratumoral dendritic cell activation and immune responses against hepatocellular carcinoma. Cancer immunology research.

Pal R, et al. (2024) Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity. Cancer research.

Mender I, et al. (2023) Activating an Adaptive Immune Response with a Telomerase-Mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. Molecular cancer therapeutics, 22(6), 737.